JY BioMed's Founder Ethan Shen, PhD, and CMO Dr. Benjamin Zhang presented the γδ T cell therapy and Anti-CEACAM6 ADC platforms at the 85th Japanese Cancer Association Annual Meeting in Kyoto. Learn more about JY BioMed's international research initiatives.

JY BioMed ADC Technology Wins Innovation Award, Eyes Global Licensing. Taiwan's JY BioMed has earned the 22nd National Innovation Award for its HCAb-ADC platform, secured FDA Orphan Drug Designation for pancreatic cancer, and published findings in Cancer Letters, as it advances international licensing partnerships across lung, pancreatic, and colorectal cancers.